Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II, N-of-1, Open-Label, Prospective Study to Evaluate the Efficacy and Safety of ATL-001 in Adult Patients With Congenital Erythropoietic Porphyria (CEP)

NCT07024316 is registered in ClinicalTrials.gov with Atlas Molecular Pharma as lead sponsor.

NCT NCT07024316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07024316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II, N-of-1, Open-Label, Prospective Study to Evaluate the Efficacy and Safety of ATL-001 in Adult Patients With Congenital Erythropoietic Porphyria (CEP)
Lead sponsor
Atlas Molecular Pharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 29, 2026
Completion date
June 1, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital erythropoietic porphyria (cep)